Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the provided metadata company name "ACHIEVE LIFE SCIENCES, INC.") on June 12, 2014. The filing addresses a specific corporate governance event regarding the departure of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the resignation of Susan Wyrick, who served as the Company's Vice President, Finance and Principal Accounting Officer. She provided notice on June 12, 2014, with the resignation effective July 11, 2014.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the immediate personnel change. No unusual items were reported.
Investor Verification Checklist
- Verify the appointment of a new Principal Accounting Officer and Vice President of Finance to replace Susan Wyrick.
- Confirm the effective date of the resignation (July 11, 2014) and any interim arrangements for financial reporting.
- Review subsequent filings to ensure the company's financial reporting capabilities remain intact following the departure of the Principal Accounting Officer.